Author: Brian G. Pierce; Zhen-Yong Keck; Ruixue Wang; Patrick Lau; Kyle Garagusi; Khadija Elkholy; Eric A. Toth; Richard A. Urbanowicz; Johnathan D. Guest; Pragati Agnihotri; Melissa C. Kerzic; Alexander Marin; Alexander K. Andrianov; Jonathan K. Ball; Roy A. Mariuzza; Thomas R. Fuerst; Steven K.H. Foung
Title: Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization Document date: 2020_4_17
ID: b6to1v4u_1
Snippet: Hepatitis C virus infects approximately 1% of the world's population, and no vaccine is currently available. Due to the high variability of HCV and its ability to actively escape the immune response, a goal of HCV vaccine design is to induce neutralizing antibodies that target conserved epitopes. Here we performed structure-based design of several epitopes of the HCV E2 envelope glycoprotein to engineer its antigenic properties. Designs were test.....
Document: Hepatitis C virus infects approximately 1% of the world's population, and no vaccine is currently available. Due to the high variability of HCV and its ability to actively escape the immune response, a goal of HCV vaccine design is to induce neutralizing antibodies that target conserved epitopes. Here we performed structure-based design of several epitopes of the HCV E2 envelope glycoprotein to engineer its antigenic properties. Designs were tested in vitro and in vivo, demonstrating alteration of the E2 antigenic profile in several cases, and one design led to improvement of cross-neutralization of heterologous viruses. This represents a proof of concept that rational engineering of HCV envelope glycoproteins can be used to modulate E2 antigenicity and optimize a vaccine for this challenging viral target.
Search related documents:
Co phrase search for related documents- actively immune response escape ability and challenging viral target: 1
- actively immune response escape ability and challenging viral target vaccine: 1
- actively immune response escape ability and challenging viral target vaccine optimize: 1
- actively immune response escape ability and concept proof: 1
- actively immune response escape ability and envelope glycoprotein: 1
- actively immune response escape ability and HCV envelope glycoprotein: 1
- actively immune response escape ability and HCV high variability: 1
- actively immune response escape and antigenic profile: 1
- actively immune response escape and challenging viral target: 1
- actively immune response escape and challenging viral target vaccine: 1
- actively immune response escape and challenging viral target vaccine optimize: 1
- actively immune response escape and concept proof: 1
- actively immune response escape and envelope glycoprotein: 1
- actively immune response escape and HCV envelope glycoprotein: 1
- actively immune response escape and HCV high variability: 1
- antigenic profile and challenging viral target: 1
- antigenic profile and challenging viral target vaccine: 1
- antigenic profile and concept proof: 1
- antigenic profile and envelope glycoprotein: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date